Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Scherer

Showing results (281-290 of 333) with videos related to

Pageof 34
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2014
The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancerAlison Backen, Andrew G Renehan, Andrew R Clamp, et al.
Heart, Lung & Circulation|May 21, 2019
Status of PCSK9 Monoclonal Antibodies in AustraliaDaniel J Scherer, Adam J Nelson, Richard O'Brien, et al.
The Journal of Experimental Medicine|July 9, 2004
Examination of Msh6- and Msh3-deficient mice in class switching reveals overlapping and distinct roles of MutS homologues in antibody diversificationZiqiang Li, Stefan J Scherer, Diana Ronai, et al.
British Journal of Cancer|February 21, 2013
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancerD W Miles, S L de Haas, L Y Dirix, et al.
The Journal of Orthopaedic and Sports Physical Therapy|February 4, 2011
Utilization of modified NFL combine testing to identify functional deficits in athletes following ACL reconstructionGregory D Myer, Laura C Schmitt, Jensen L Brent, et al.
Angiogenesis|February 22, 2014
Genetic markers of bevacizumab-induced hypertensionDiether Lambrechts, Matthieu Moisse, Paul Delmar, et al.
Angiogenesis|July 12, 2014
Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapySanne de Haas, Paul Delmar, Aruna T Bansal, et al.
British Journal of Cancer|June 29, 2016
Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumabCong Zhou, Andrew Clamp, Alison Backen, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2008
Distinct effects of the recurrent Mlh1G67R mutation on MMR functions, cancer, and meiosisElena Avdievich, Cora Reiss, Stefan J Scherer, et al.
The Journal of Experimental Medicine|May 3, 2000
Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activationT Brdicka, D Pavlistová, A Leo, et al.
Pageof 34

Showing results (281-290 of 333) with videos related to

Sort By:
Pageof 34
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2014
The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancerAlison Backen, Andrew G Renehan, Andrew R Clamp, et al.
Heart, Lung & Circulation|May 21, 2019
Status of PCSK9 Monoclonal Antibodies in AustraliaDaniel J Scherer, Adam J Nelson, Richard O'Brien, et al.
The Journal of Experimental Medicine|July 9, 2004
Examination of Msh6- and Msh3-deficient mice in class switching reveals overlapping and distinct roles of MutS homologues in antibody diversificationZiqiang Li, Stefan J Scherer, Diana Ronai, et al.
British Journal of Cancer|February 21, 2013
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancerD W Miles, S L de Haas, L Y Dirix, et al.
The Journal of Orthopaedic and Sports Physical Therapy|February 4, 2011
Utilization of modified NFL combine testing to identify functional deficits in athletes following ACL reconstructionGregory D Myer, Laura C Schmitt, Jensen L Brent, et al.
Angiogenesis|February 22, 2014
Genetic markers of bevacizumab-induced hypertensionDiether Lambrechts, Matthieu Moisse, Paul Delmar, et al.
Angiogenesis|July 12, 2014
Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapySanne de Haas, Paul Delmar, Aruna T Bansal, et al.
British Journal of Cancer|June 29, 2016
Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumabCong Zhou, Andrew Clamp, Alison Backen, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2008
Distinct effects of the recurrent Mlh1G67R mutation on MMR functions, cancer, and meiosisElena Avdievich, Cora Reiss, Stefan J Scherer, et al.
The Journal of Experimental Medicine|May 3, 2000
Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activationT Brdicka, D Pavlistová, A Leo, et al.
Pageof 34